Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Allogenic Adoptive Immune Therapy for Advanced AIDS Patients

NCT02651376 is registered in ClinicalTrials.gov with Beijing 302 Hospital as lead sponsor.

NCT NCT02651376
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02651376 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Allogenic Adoptive Immune Therapy for Advanced AIDS Patients
Lead sponsor
Beijing 302 Hospital
Phase
Phase 1/2
Overall status
Completed
Start date
September 30, 2015
Completion date
August 31, 2017
Enrollment
20 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

human immunodeficiency virus, immunodeficiency